- Public Comps
- MiMedx Group
MiMedx Group Valuation Multiples
Discover MiMedx Group's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Aquestive Therapeutics, Chong Kun Dang Pharma, Zentiva, Agomab Therapeutics and more.
MiMedx Group Overview
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Founded
2008
HQ

Employees
837
Website
Financials (LTM)
EV
$540M
Valuation Multiples
Start free trialMiMedx Group Financials
MiMedx Group reported last 12-month revenue of $319M and EBITDA of $32M.
In the same LTM period, MiMedx Group generated $245M in gross profit, $32M in EBITDA, and $499K in net income.
Revenue (LTM)
MiMedx Group P&L
In the most recent fiscal year, MiMedx Group reported revenue of $419M and EBITDA of $78M.
MiMedx Group is profitable as of last fiscal year, with gross margin of 83%, EBITDA margin of 19%, and net margin of 12%.
Financial data powered by Morningstar, Inc.
MiMedx Group Stock Performance
MiMedx Group has current market cap of $659M, and enterprise value of $540M.
Market Cap Evolution
MiMedx Group's stock price is $4.52.
MiMedx Group share price decreased by 0.4% in the last 30 days, and by 35.2% in the last year.
MiMedx Group has an EPS (earnings per share) of $0.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $540M | $659M | -0.4% | -0.4% | 14.9% | -35.2% | $0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMiMedx Group Valuation Multiples
MiMedx Group trades at 1.7x EV/Revenue multiple, and 17.0x EV/EBITDA.
EV / Revenue (LTM)
MiMedx Group Financial Valuation Multiples
As of September 2, 2026, MiMedx Group has market cap of $659M and EV of $540M.
MiMedx Group has a P/E ratio of 1320.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MiMedx Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


MiMedx Group Margins & Growth Rates
MiMedx Group decreased revenue by 36% and EBITDA by 105% in the last fiscal year.
In the most recent fiscal year, MiMedx Group reported gross margin of 83%, EBITDA margin of 19%, and net margin of 12%.
MiMedx Group Margins
MiMedx Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
MiMedx Group Operational KPIs
MiMedx Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
MiMedx Group's Rule of 40 is (37%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MiMedx Group's Rule of X is (90%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
MiMedx Group Competitors
MiMedx Group competitors include Aquestive Therapeutics, Chong Kun Dang Pharma, Zentiva, Agomab Therapeutics, AngioDynamics, Sagimet Biosciences, Cormedix, Crescent Biopharma, Prime Medicine and SS Innovations.
Most MiMedx Group public comparables operate across Biopharmaceuticals, Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 13.9x | 12.8x | (8.8x) | (16.9x) | |||
| 0.6x | 0.6x | 8.1x | 8.6x | |||
| 5.0x | - | 16.6x | - | |||
| - | - | (5.2x) | (4.5x) | |||
| 1.9x | 1.8x | (46.0x) | 35.0x | |||
| - | - | (7.3x) | - | |||
| 1.7x | 1.6x | 3.3x | - | |||
| 46.2x | 103.9x | (3.3x) | - | |||
This data is available for Pro users. Sign up to see all MiMedx Group competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by MiMedx Group
MiMedx Group has acquired 2 companies to date.
Last acquisition by MiMedx Group was on July 28th 2026. MiMedx Group acquired Sanara MedTech for $350M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by MiMedx Group
| Description | Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. | Stability Biologics is a U.S. distributor of human allograft tissues for orthopedic, spine, and wound care procedures, supplying processed bone and soft tissue grafts to over 1,000 surgeons and ambulatory centers nationwide. Based in Louisville, Kentucky, the company partners with tissue banks for sterile, terminally sterilized products like demineralized bone matrix used in spinal fusions. Stability Biologics expanded to dental applications in 2022, maintaining AATB accreditation for quality standards. |
| HQ Country | ||
| HQ City | - | San Antonio, TX |
| Deal Date | 28 Jul 2026 | 10 Jan 2016 |
| Valuation | $350M | $10M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all MiMedx Group acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MiMedx Group
| When was MiMedx Group founded? | MiMedx Group was founded in 2008. |
| Where is MiMedx Group headquartered? | MiMedx Group is headquartered in United States. |
| How many employees does MiMedx Group have? | As of today, MiMedx Group has over 837 employees. |
| Who is the CEO of MiMedx Group? | MiMedx Group's CEO is Joseph H. Capper. |
| Is MiMedx Group publicly listed? | Yes, MiMedx Group is a public company listed on Nasdaq. |
| What is the stock symbol of MiMedx Group? | MiMedx Group trades under MDXG ticker. |
| When did MiMedx Group go public? | MiMedx Group went public in 2007. |
| Who are competitors of MiMedx Group? | MiMedx Group main competitors include Aquestive Therapeutics, Chong Kun Dang Pharma, Zentiva, Agomab Therapeutics, AngioDynamics, Sagimet Biosciences, Cormedix, Crescent Biopharma, Prime Medicine, SS Innovations. |
| What is the current market cap of MiMedx Group? | MiMedx Group's current market cap is $659M. |
| What is the current revenue of MiMedx Group? | MiMedx Group's last 12 months revenue is $319M. |
| What is the current revenue growth of MiMedx Group? | MiMedx Group revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of MiMedx Group? | Current revenue multiple of MiMedx Group is 1.7x. |
| What is the current EBITDA of MiMedx Group? | MiMedx Group's last 12 months EBITDA is $32M. |
| What is MiMedx Group's EBITDA margin? | MiMedx Group's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of MiMedx Group? | Current EBITDA multiple of MiMedx Group is 17.0x. |
| What is the current FCF of MiMedx Group? | MiMedx Group's last 12 months FCF is $19M. |
| What is MiMedx Group's FCF margin? | MiMedx Group's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of MiMedx Group? | Current FCF multiple of MiMedx Group is 28.9x. |
| How many companies MiMedx Group has acquired to date? | As of September 2026, MiMedx Group has acquired 2 companies. |
| What was the largest acquisition by MiMedx Group? | $350M acquisition of Sanara MedTech on 28th July 2026 was the largest M&A MiMedx Group has done to date. |
| What companies MiMedx Group acquired? | MiMedx Group acquired Sanara MedTech and Stability Biologics. |
| In how many companies MiMedx Group has invested to date? | MiMedx Group hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to MiMedx Group
Lists including MiMedx Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





